[Therapeutic effect of deoxyribonucleotidum on acute viral myocarditis].

OBJECTIVE: To evaluate the therapeutic efficacy of deoxyribonucleotidum in treatment of acute viral myocarditis. METHODS: Eighty-eight patients with acute viral myocarditis were randomized equally into therapeutic group and control group. Patients in the control group were treated with routine treatment and those in the therapeutic group were given deoxyribonucleotidum in addition to routine treatment. After 4 weeks, the total efficacy rate and median time of symptom disappearance were compared between the two groups. RESULTS: The total efficacy rate in the control and therapeutic groups was 79.54% and 95.45% (P=0.049), and the median time of symptom disappearance was 9.5 days and 6.5 days, respectively (P=0.035). Hypotension and mild dizziness were found in 2 patients in the therapeutic group without other severe side effects. CONCLUSION: Deoxyribonucleotidum can improve the therapeutic effect for acute viral myocarditis.

[Clinical significance of protein Z alteration in patients with cardio-cerebral thrombotic diseases].

OBJECTIVE: To study the alteration of protein Z (PZ) in patients with cardio-cerebral thrombotic diseases, its clinical significance and relations with FX. METHODS: PZ and FX:Ag were measured by ELISA, and plasma FX:C by first stage method. In 170 patients with acute ischemic stroke (AIS), 40 acute myocardial infarction (AMI) and 60 healthy adults as contrast, PZ, FX:C and FX:Ag were measured and compared between incipience and recurrence, different ages and genders. RESULTS: In AIS and AMI groups, PZ levels decreased significantly to (940.02 +/- 229.82) microg/L and (1071.44 +/- 180.52) microg/L, respectively \[the contrast group was (2257.97 +/- 479.76) microg/L, P < 0.001\]. But FX:C and FX:Ag raised to (136.73 +/- 34.93)% and (135.54 +/- 54.39)% in AIS group; and to (139.53 +/- 29.18)%, (129.75 +/- 21.91)% in AMI group, respectively, while in the contrast group they were (94.33 +/- 22.00)% and (77.22 +/- 13.19)% (P < 0.001). In the comparative research between the AIS group, AMI group and the contrast group, PZ level was clearly found to negatively relate to the level of FX:C and FX:Ag (P < 0.001). Meanwhile, PZ level, FX:C and FX:Ag in recur-AIS group and recur-AMI group exhibited significant differences (P < 0.05) from those in the primary AIS and AMI groups, suggesting that the decrease of PZ levels reflected the pathological process of the disease. In addition, PZ level gradually decreased with the increase of age (P < 0.05), while FX:C and FX:Ag had no relations with age (P > 0.05). No correlation was found in sex with PZ level, FX:C, FX:Ag (P > 0.05). CONCLUSION: PZ level was significantly decreased in AIS and AMI patients and was negatively related to FX:C and FX:Ag. The mechanism leading to FX increase may partially related with the decreased of PZ. PZ level was different in the primary and recurrent disease and was gradually decreased with the increase of age. Lack of PZ might be a etiological factor of cardio-cerebral thrombotic diseases.